AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3122349 — intervention group
Group type: COMPARATOR
Intervention: No Mannitol (control group)
Number of subjects: 31
Study 3122349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 31
Study 29068724 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention targeting young adults for improving dietary choices
Number of subjects: 68
Study 26959498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi group
Number of subjects: 100
Study 26959498 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 100
Study 24461900 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 2 weeks
Number of subjects: 276
Study 24461900 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 276
Study 24461900 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 4 weeks
Number of subjects: 276
Study 24461900 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 276
Study 24461900 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 276
Study 24461900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 22623266 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg risperidone
Number of subjects: 80
Study 22403977 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free mouthwash containing 0.075% CPC and 0.05% NaF
Number of subjects: 110
Study 22403977 — intervention group
Group type: COMPARATOR
Intervention: Control mouthwash containing only 0.05% NaF
Number of subjects: 110
Study 17624606 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (HBE) rehabilitation group, n = 16
Number of subjects: 27
Study 17624606 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (UC), n = 11
Number of subjects: 27
Study 17624606 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 16631000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac
Number of subjects: 44
Study 16631000 — intervention group
Group type: COMPARATOR
Intervention: CyA
Number of subjects: 44
Study 14598509 — intervention group
Group type: EXPERIMENTAL
Intervention: Segment resection + axillar dissection + radiotherapy
Number of subjects: 1083
Study 14598509 — intervention group
Group type: COMPARATOR
Intervention: Petey-Dyson mastectomy
Number of subjects: 1083
Study 14598509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy by progestagens and antiestrogens
Number of subjects: 1083
Study 11304054 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIK vaccine
Number of subjects: 73
Study 11304054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8652317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 36
Study 8652317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 36
Study 8652317 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ropivacaine
Number of subjects: 36
Study 8652317 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 36
Study 1999706 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm A)
Number of subjects: 168
Study 1999706 — intervention group
Group type: COMPARATOR
Intervention: MTX 200 mg/m2 followed by 5-FU 600 mg/m2 (arm B)
Number of subjects: 168
Study 6095656 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists (ranitidine and cimetidine)
Number of subjects: 0
Study 6095656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6095656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and cimetidine
Number of subjects: 0
Study 31778471 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer restorations (ART/HVGIC)
Number of subjects: 66
Study 31778471 — intervention group
Group type: COMPARATOR
Intervention: Conventional resin composite restorations (CRT)
Number of subjects: 66
Study 28771864 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine Care for Nurses programme (3 months duration)
Number of subjects: 137
Study 28771864 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief written lifestyle guidance)
Number of subjects: 137
Study 27142078 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily assisted exercise intervention (n = 13)
Number of subjects: 34
Study 27142078 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily assisted exercise intervention (n = 11)
Number of subjects: 34
Study 27142078 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control, n = 10)
Number of subjects: 34
Study 25315942 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (beta-blocker)
Number of subjects: 41
Study 25315942 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 41
Study 25315942 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study 21861845 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB therapy (losartan, 100 mg/day)
Number of subjects: 53
Study 21861845 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 53
Study 20653945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (approximately 250 microg/m3) during intermittent exercise for one hour
Number of subjects: 18
Study 20653945 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure during intermittent exercise for one hour
Number of subjects: 18
Study 17439735 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic auto‐transplantation and oesophageal transection anastomosis
Number of subjects: 274
Study 17439735 — intervention group
Group type: COMPARATOR
Intervention: Splenic auto‐transplantation
Number of subjects: 274
Study 16295811 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic transport ventilator (ATV)
Number of subjects: 28
Study 16295811 — intervention group
Group type: COMPARATOR
Intervention: Bag valve (BV)
Number of subjects: 28
Study 12073199 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (bolus 0.25 mg/kg followed by continuous infusion of 1.7 microg/kg/min) (DTZ, n = 12)
Number of subjects: 24
Study 12073199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C, n = 12)
Number of subjects: 24
Study 9799972 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng (4.5 g/day)
Number of subjects: 34
Study 7701397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicle screw/plate system
Number of subjects: 28
Study 7701397 — intervention group
Group type: COMPARATOR
Intervention: Non-instrumented control (literature controls)
Number of subjects: 28
Study 2649743 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (20 u/kg)
Number of subjects: 49
Study 2649743 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn patients (10-70% body surface area)
Number of subjects: 49
Study 401853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 0
Study 401853 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 0
Study 401853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (for gram-negative bacilli infections)
Number of subjects: 0
Study 401853 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (for gram-negative bacilli infections)
Number of subjects: 0
Study 29172739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity aquatic exercise program for 12 weeks
Number of subjects: 16
Study 27075924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 2942
Study 27075924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2942
Study 25773557 — intervention group
Group type: EXPERIMENTAL
Intervention: Time trade-off (TTO) responses
Number of subjects: 22225
Study 25773557 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired comparison responses
Number of subjects: 22225
Study 23720197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 364
Study 20499747 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 0
Study 20499747 — intervention group
Group type: COMPARATOR
Intervention: No-tourniquet group
Number of subjects: 0
Study 20499747 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 18956979 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 791
Study 18956979 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 791
Study 16513608 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐IMP SPECT
Number of subjects: 19
Study 16513608 — intervention group
Group type: COMPARATOR
Intervention: 18F‐FDG PET
Number of subjects: 19
Study 12661673 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness training
Number of subjects: 0
Study 10759280 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate spray
Number of subjects: 0
Study 10759280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8633409 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcapsular orchiectomy
Number of subjects: 74
Study 8633409 — intervention group
Group type: COMPARATOR
Intervention: Total orchiectomy
Number of subjects: 74
Study 8633409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 74
Study 1378689 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 145
Study 1378689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 6476545 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic external defibrillator (AED)
Number of subjects: 0
Study 6476545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR) instruction with AED
Number of subjects: 0
Study 6476545 — intervention group
Group type: COMPARATOR
Intervention: CPR instruction alone
Number of subjects: 0
Study 31405706 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol supplementation for 4 weeks
Number of subjects: 43
Study 31405706 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 43
Study 29159538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity conditions (RPE = 16)
Number of subjects: 7
Study 29159538 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity conditions (RPE = 12)
Number of subjects: 7
Study 27721537 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (Group A)
Number of subjects: 90
Study 27721537 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (Group B)
Number of subjects: 90
Study 27721537 — intervention group
Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 90
Study 24276777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse navigator support for 4 months
Number of subjects: 251
Study 24276777 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 251
Study 23024023 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 7 days
Number of subjects: 40
Study 23024023 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Inhaled Corticosteroid (DOICS) treatment with budesonide 1,600 μg for 5 days
Number of subjects: 40
Study 23024023 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe(NO) test for nonadherence
Number of subjects: 40
Study 23024023 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective validation of the Fe(NO) test
Number of subjects: 40
Study 20304584 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron reduction (phlebotomy)
Number of subjects: 100
Study 20304584 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin administration
Number of subjects: 100
Study 20304584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin levels
Number of subjects: 100
Study 17627681 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. hydralazine (5 mg doses)
Number of subjects: 124
Study 17627681 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐bolus diazoxide (15 mg doses)
Number of subjects: 124
Study 17627681 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 124
Study 15954919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 44
Study 15954919 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 44
Study 12098159 — intervention group
Group type: EXPERIMENTAL
Intervention: Real low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Number of subjects: 11
Study 12098159 — intervention group
Group type: COMPARATOR
Intervention: Sham low-level laser therapy (LLLT) plus microamperes transcutaneous electric nerve stimulation (TENS)
Number of subjects: 11
Study 10073725 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM + BCG
Number of subjects: 2453
Study 10073725 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 2453
Study 10073725 — intervention group
Group type: EXPERIMENTAL
Intervention: LST responders on day 80 (> or =5 mm)
Number of subjects: 2453
Study 7744087 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg o.m.
Number of subjects: 43
Study 7744087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg b.d.
Number of subjects: 43
Study 7744087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 2289097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural problem solving
Number of subjects: 20
Study 2289097 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 20
Study 6271049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1.0 g) intramuscularly
Number of subjects: 97
Study 6271049 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 x 10(6) U) intramuscularly with 1 g of probenecid orally
Number of subjects: 97
Study 30642667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 86
Study 30642667 — intervention group
Group type: COMPARATOR
Intervention: No oral anticoagulation (non-OAC)
Number of subjects: 86
Study 28256356 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of intensive speech and language therapy (≥10 hours per week)
Number of subjects: 158
Study 28256356 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks deferral of intensive speech and language therapy
Number of subjects: 158
Study 26553106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 26553106 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study 24045249 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mmol/kg gadofosveset
Number of subjects: 30
Study 24045249 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mmol/kg gadofosveset
Number of subjects: 30
Study 24045249 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mmol/kg gadofosveset
Number of subjects: 30
Study 21177034 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute resistance training
Number of subjects: 198
Study 21177034 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-minute resistance training
Number of subjects: 198
Study 21177034 — intervention group
Group type: COMPARATOR
Intervention: Control group (weekly information on general health)
Number of subjects: 198
Study 20355166 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (250 mg Sustanon) administered weekly for five weeks
Number of subjects: 47
Study 20355166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17855669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus autologous stem cells
Number of subjects: 100
Study 17855669 — intervention group
Group type: COMPARATOR
Intervention: Melphalan plus high-dose dexamethasone
Number of subjects: 100
Study 17855669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus autologous stem cells (low-risk disease)
Number of subjects: 100
Study 17855669 — intervention group
Group type: COMPARATOR
Intervention: Melphalan plus high-dose dexamethasone (low-risk disease)
Number of subjects: 100
Study 17855669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus autologous stem cells (high-risk disease)
Number of subjects: 100
Study 17855669 — intervention group
Group type: COMPARATOR
Intervention: Melphalan plus high-dose dexamethasone (high-risk disease)
Number of subjects: 100
Study 15649112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program
Number of subjects: 541
Study 11552963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild pH neutral soap and water
Number of subjects: 140
Study 11552963 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 140
Study 9559773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (2 g administered every 12 h)
Number of subjects: 115
Study 9559773 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1 g administered every 12 h)
Number of subjects: 115
Study 9559773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 115
Study 9559773 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 115
Study 7524917 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation (BDP)
Number of subjects: 30
Study 7524917 — intervention group
Group type: COMPARATOR
Intervention: Transurethral incision of the prostate (TUIP)
Number of subjects: 30
Study 3665393 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg administered alone
Number of subjects: 8
Study 3665393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered concurrently with antacid (62 mL of aluminum and magnesium hydroxide suspension)
Number of subjects: 8
Study 3665393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered with antacid one hour after the ibuprofen dose
Number of subjects: 8
Study 3665393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg administered concurrently with antacid plus three more antacid doses given every five hours
Number of subjects: 8
Study 31898090 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM)
Number of subjects: 56
Study 31898090 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 56
Study 31898090 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 56
Study 31898090 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (EM and CM)
Number of subjects: 56
Study 29450332 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal ultrasound mode
Number of subjects: 52
Study 29450332 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional ultrasound mode
Number of subjects: 52
Study 24299501 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXThaler
Number of subjects: 66
Study 23542612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketoprofen 50 mg
Number of subjects: 1395
Study 23542612 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketoprofen 100 mg
Number of subjects: 1395
Study 23542612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen-free vehicle 2.2 g (TDT 064)
Number of subjects: 1395
Study 23542612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen-free vehicle 4.4 g (TDT 064)
Number of subjects: 1395
Study 23542612 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral celecoxib 100 mg
Number of subjects: 1395
Study 23542612 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 1395
Study 20976815 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colpopexy or autologous fascial sling
Number of subjects: 655
Study 18218783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion 1 (before fingolimod administration)
Number of subjects: 14
Study 18218783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod administration
Number of subjects: 14
Study 18218783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion 2 (in the presence of fingolimod)
Number of subjects: 14
Study 18218783 — intervention group
Group type: EXPERIMENTAL
Intervention: Total isoproterenol dose with fingolimod
Number of subjects: 14
Study 18218783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusions 3 to 5
Number of subjects: 14
Study 18218783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 14
Study 18218783 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 14
Study 16752097 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom curricula
Number of subjects: 0
Study 16752097 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leadership
Number of subjects: 0
Study 16752097 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-driven/led extra-curricular activities
Number of subjects: 0
Study 16752097 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent involvement programs
Number of subjects: 0
Study 16752097 — intervention group
Group type: EXPERIMENTAL
Intervention: Community activism
Number of subjects: 0
Study 12728219 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef-containing diet
Number of subjects: 21
Study 12728219 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 21
Study 11701431 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate
Number of subjects: 61
Study 11701431 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate
Number of subjects: 61
Study 11701431 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate
Number of subjects: 61
Study 11701431 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 61
Study 11701431 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate
Number of subjects: 61
Study 11701431 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist plus graded doses of testosterone
Number of subjects: 61
Study 11701431 — intervention group
Group type: COMPARATOR
Intervention: Control (GnRH agonist only)
Number of subjects: 61